


MIC for selected compounds.

MIC (µg/ml)	<i>S. flexneri</i>	<i>Y. pestis</i>	<i>F. tularensis</i>	<i>B. anthracis</i>	<i>M. tuberculosis</i>	<i>S. aureus</i>
KKL-35	2	1	0.1	0.25	<1.5	0.2
KKL-40	18	8	0.03	0.1	<1.5	0.2
KKL-55	0.8	16	0.5	6.6	10	16
KKL-10	1.2		0.1	0.3	>50	0.5



Inhibitor Structure of Select Pathogens

## Technology Summary

The researchers have developed methods and compositions of matter relating to inhibitors of the tmRNA pathway. These potential therapeutics have antibacterial activity with broad species specificity, including *B. anthracis* and other pathogens of military and civilian interest. Identified compositions have been demonstrated to kill bacterial pathogens when added exogenously. Proof-of-concept animal testing is underway.

## Application & Market Utility

Antibiotic-resistant infections are increasingly difficult to treat and cost \$20 billion per year in direct healthcare costs. The subject antibiotics provide a new target for antibiotics and new chemical scaffolds with potent efficacy that can be used to treat infections in humans and/or animals. The researchers' top inhibitors are as effective as antibiotics in clinical use. They do not exhibit cross-resistance with any existing compounds.

## Next Steps

Seeking research collaboration and licensing opportunities.

### TECHNOLOGY READINESS LEVEL

1-3

#### Seeking

Investment | Licensing | Research

#### Keywords

- Drug Discovery
- Antibiotics
- HTS Target Identification

#### Researchers

##### Kenneth Keiler

Professor of Biochemistry and Molecular Biology

[Online Bio](#)

##### Stephen Benovic

Evan Pugh University Professor and Eberly Chair in Chemistry

#### Originating College

Eberly College of Science

#### Office of Technology Management Contact

Long, Melissa  
mkl137@psu.edu  
814-865-5730